The drumbeat of Alzheimer’s PhIII failures continues as vTv drug is outperformed by a placebo, shares crash
The execs at vTv $VTVT have put another nail in the coffin of recycled Alzheimer’s drug programs.
The biotech, which floated an IPO on the back of an idea that it could take a failed drug from Pfizer and make it work based on some retrospective data analysis (sound familiar?), reported Monday afternoon that their lead therapy azeliragon failed a Phase III study for mild to moderate Alzheimer’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
